BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that a U.S. patent related to wound healing has been issued by the U.S. Patent and Trademark Office. The patent claims are based on a significant body of data developed by the National Institutes of Health and include numerous claims relating to Thymosin beta 4 (Tß4), its analogues, related compounds, fragments and other variants.
